Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Mutations in DNA Repair Genes Affect Survival in Prostate Cancer

Mutations in DNA Repair Genes Affect Survival in Prostate Cancer

According to a noteworthy prostate cancer study at ESMO 2017, inherited mutations in DNA repair genes were associated with shorter survival in metastatic prostate cancer resistant to hormonal therapy (castration).

Of cancers, 10 percent are caused by inherited (germline) mutations. Most of these mutations occur in DNA repair genes. Although some mutations in DNA repair genes have been associated with shorter survival in prostate cancer, in metastatic prostate cancer resistant to hormone therapy there had been no study of the relationship between germline mutations and life-prolonging treatments. ESMO 2017 presented a study observing that hormone therapy-resistant prostate cancer patients with mutations in DNA repair genes had a poor disease course and survival.

You May Be Interested In:

The multicenter observational PROREPAIR-Bstudy included patients with newly diagnosed metastatic (stage 4) hormone therapy-resistant resistant prostate cancer and unknown germline mutation status. Between January 2013 and April 2016, from 36 institutions in Spain, patients treated with abiraterone, enzalutamide, docetaxel, cabazitaxel and Ra-223 totaled 419 study participants. Researchers analyzed samples collected from these patients for inherited mutations in BRCA1, BRCA2, ATM and PALB2 genes, identifying the effects of these mutations on disease development and first-line life-prolonging treatments.

According to the Research Results

  • A total of 26 patients were identified as carriers of inherited gene mutations. Of these, 14 carried mutations in BRCA2, 8 in ATM and 4 in BRCA1.
  • In carriers, the interval from starting androgen-lowering treatment (abiraterone and enzalutamide) to metastatic disease was shorter. It was 23.7 months in carriers and 26.7 in noncarriers. In BRCA2 carriers, the interval was 18 months.
  • Survival was shorter in carriers than in noncarriers. It was 28.5 months in carriers and 36 months in noncarriers. In BRCA2 carriers, survival was particularly short (17.4 months).
  • Among patients receiving taxane chemotherapy (docetaxel and cabazitaxel), disease-free survival was 7.8 months in carriers and 7.1 months in noncarriers.

In conclusion, no significant difference was found when comparing disease-free survival between inherited mutation carriers and noncarriers. However, the disease course is particularly poor in BRCA2 carriers.

You may be interested in:

Sources

Castro Marcos E, et al. PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC).

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Mutations in DNA Repair Genes Affect Survival in Prostate Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy